1032 related articles for article (PubMed ID: 20844345)
21. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
22. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
[TBL] [Abstract][Full Text] [Related]
23. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
27. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
28. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
29. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
31. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
32. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
34. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
35. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
[TBL] [Abstract][Full Text] [Related]
36. Emerging treatments in chemotherapy-induced nausea and vomiting.
Grunberg SM; Slusher B; Rugo HS
Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
[TBL] [Abstract][Full Text] [Related]
37. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari RM
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
[TBL] [Abstract][Full Text] [Related]
38. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
39. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]